MX2013013785A - Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa. - Google Patents

Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.

Info

Publication number
MX2013013785A
MX2013013785A MX2013013785A MX2013013785A MX2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A MX 2013013785 A MX2013013785 A MX 2013013785A
Authority
MX
Mexico
Prior art keywords
approximately
days
antibody
available
ifn
Prior art date
Application number
MX2013013785A
Other languages
English (en)
Spanish (es)
Inventor
Ryan Criste
Lorin Roskos
Wendy White
Dominique Ethgen
Rajesh Narwal
Gabriel Robbie
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2013013785A publication Critical patent/MX2013013785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2013013785A 2011-05-25 2012-05-23 Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa. MX2013013785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489949P 2011-05-25 2011-05-25
PCT/US2012/039098 WO2012162367A1 (en) 2011-05-25 2012-05-23 Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Publications (1)

Publication Number Publication Date
MX2013013785A true MX2013013785A (es) 2014-07-28

Family

ID=47217695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013785A MX2013013785A (es) 2011-05-25 2012-05-23 Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.

Country Status (9)

Country Link
EP (1) EP2714080A4 (pt)
JP (1) JP2014516970A (pt)
KR (1) KR20140043402A (pt)
CN (1) CN103732251A (pt)
BR (1) BR112013030242A2 (pt)
CA (1) CA2836926A1 (pt)
MX (1) MX2013013785A (pt)
RU (1) RU2013157177A (pt)
WO (1) WO2012162367A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP6640717B2 (ja) * 2013-06-15 2020-02-05 トカジェン インコーポレーテッド レトロウイルス複製ベクターと関連する免疫抑制成分
CN103740755A (zh) * 2013-12-23 2014-04-23 中国农业大学 猪ifit1基因在抗prrs病毒中的应用
CN107058521B (zh) * 2017-03-17 2019-12-27 中国科学院北京基因组研究所 一种检测人体免疫状态的检测系统
CN113196406A (zh) * 2018-10-11 2021-07-30 维维雅生物技术公司 用于确定在被诊断患有疾病的受试者中使用药物组合进行治疗的功效的方法以及用于将药物组合在所述受试者的治疗中的效用分类的方法
KR20210084528A (ko) 2018-10-26 2021-07-07 얀센 바이오테크 인코포레이티드 I형 인터페론 시그너처 및 사용 방법
JP2022527542A (ja) * 2019-04-04 2022-06-02 ヤンセン バイオテツク，インコーポレーテツド 抗ＩＦＮ－α／ω抗体の投与方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
PT1711207E (pt) * 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
US20070110757A1 (en) * 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
AU2008324800B2 (en) * 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
CN102083859B (zh) * 2008-05-07 2014-09-17 阿哥斯医疗公司 人源化抗人干扰素-α抗体
US20110256149A1 (en) * 2008-10-09 2011-10-20 Medimmune, Llc Antibody formulation
JP6211513B2 (ja) * 2011-04-26 2017-10-11 ジェネンテック， インコーポレイテッド 自己免疫疾患の治療のための組成物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580301C1 (ru) * 2015-04-21 2016-04-10 Людмила Николаевна Хон Способ лечения системной красной волчанки человека

Also Published As

Publication number Publication date
KR20140043402A (ko) 2014-04-09
WO2012162367A1 (en) 2012-11-29
JP2014516970A (ja) 2014-07-17
CN103732251A (zh) 2014-04-16
BR112013030242A2 (pt) 2016-12-06
EP2714080A1 (en) 2014-04-09
EP2714080A4 (en) 2014-11-19
CA2836926A1 (en) 2012-11-29
RU2013157177A (ru) 2015-06-27

Similar Documents

Publication Publication Date Title
MX2013013785A (es) Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa.
CA2607697C (en) Treating and evaluating inflammatory disorders
CN110769851B (zh) 兽用抗il31抗体
JP7123225B2 (ja) 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
KR102527840B1 (ko) 인터페론 베타 항체 및 그의 용도
JP2023506922A (ja) アトピー性皮膚炎を処置するための二重特異性イヌ化抗体
CN104159919A (zh) 使用抗干扰素γ抗体的治疗方法
JP7008020B2 (ja) ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
KR20200015477A (ko) 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체
KR20130137688A (ko) 베타7 인테그린 길항제를 투여하는 방법
JP2021503888A (ja) 抗ｃｘｃｒ５抗体、その組成物及びその使用
RU2539034C2 (ru) Лечение рассеянного склероза
US20240076382A1 (en) CD1a ANTIBODIES AND USES THEREOF
US20220389089A1 (en) Anti-il-27 antibodies and uses thereof
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
WO2023233330A1 (en) Anti-bmp9 antibodies and methods of use thereof
KR20230145929A (ko) CD1a 항체 및 그의 용도
CN118076635A (zh) 抗il-27抗体和其用途

Legal Events

Date Code Title Description
FA Abandonment or withdrawal